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EUROPEAN REGULATION AFFECTING NANOMATERIALS - REVIEW OF
LIMITATIONS AND FUTURE RECOMMENDATIONS
Steffen Foss Hansen, Anders Baun  Department of Environmental Engineering,
Technical University of Denmark
 After learning about the potential risks associated with various specific nanomaterials,
concerns have been raised about adequacy of existing regulation in Europe and what
should be done to address any potential regulatory gaps related to nanomaterials.
Understanding the limitations of the current regulation in regard to nanomaterials is a
starting point in a democratic and transparent process towards adapting existing laws and
facilitating an informed discussion about which kind of regulatory options best address the
identified limitations. In the following we will introduce key pieces of European legislation
affecting nanomaterials, analyze their limitations, and provide a number of recommenda-
tions on how these can be overcome. We find that, although nanomaterials are in principle
covered by the scope of many of the existing legislative frameworks, it is often unclear, if
current regulations are actually applicable when it comes to specific nanomaterials and
their diverse applications. Main limitations seem to be: that requirements to do safety eval-
uations are triggered by production volumes by tonnage not tailored to the nanoscale, the
profound lack of (eco)toxicological data, and that thresholds values and occupational
exposure limits cannot be established with existing methodologies.
Keywords: Nanomaterials, European legislation, REACH, cosmetics, pharmaceutical regulation, food
laws, worker safety directives, waste directives
INTRODUCTION
After learning about the potential risks associated with various specif-
ic nanomaterials such as C60, long carbon nanotubes, and nanosilver,
one of the first logical questions for many politicians, regulators, aca-
demics and members of the public has been whether existing regulation
is adequate in the short and the long term and what should be and is
being done to address any potential regulatory gaps related to nanotech-
nology and nanomaterials (RS and RAE 2004, Macoubrie 2005,
Chaundry et al. 2006, Gavelin et al. 2007).
The Commission of the European Communities has adopted a so-
called incremental approach which focuses on adapting existing laws to
regulate nanotechnologies and amending them in order to deal with
nanomaterials. Understanding the limitations of the current regulation
in regard to nanomaterials is a starting point in a democratic and trans-
parent process towards adapting existing laws and facilitating an
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informed discussion about which kind of regulatory options best address
the identified limitations.
In this paper we provide an analysis of key pieces of European regu-
lation affecting nanomaterials including REACH, cosmetics regulation,
pharmaceutical regulation, the worker safety directives, the waste direc-
tives and we identify key limitations and provide recommendations on
how these can be overcome.
REGISTRATION, EVALUATION AND AUTHORIZATION OF CHEMICALS
(REACH)
One of the key pieces of European legislation affecting nanomateri-
als is Regulation (EC) No 1907/2006 of the European Parliament and of
the Council of the European Union called Registration, Evaluation and
Authorization of Chemicals (REACH). REACH went into force mid-2007
(EP and CEU 2006). In short, the REACH consists of four elements:
1. Registration—Data collection on chemical use and toxicity.
2. Evaluation—Examination by governments of the need for additional
testing and regulation of chemicals.
3. Authorization of chemicals—Requirements for firms to seek permis-
sion to use chemicals of high concern; and
4. Restrictions or complete ban of certain chemicals that cannot be used
safely.
Except for the evaluation and restrictions process under REACH,
there is a general shift of the responsibility in the registration and author-
ization process of REACH onto manufacturers and importers to provide
data and information (including downstream users of chemicals). The
registration process will happen gradually and by 30 November, 2010 man-
ufacturers and importers had to register substances produced or import-
ed in more than 100 tonnes per year. The same applied for substances pro-
duced in more than a 100 tons that have been classified as very toxic to
aquatic organisms and substances produced in more than 1 ton that have
been classified under Cat 1 or 2 carcinogens, mutagens or reproductive
toxicants. By 1 June 2013 producers or importers of substances in quanti-
ties of more than 100 tons have to register and by 1 June 2018, registration
of substances produced in more than 10 tons has to be completed (EP and
CEU 2006, art. 23).
Although a number of substances, e.g. nanosilver and various forms
of carbon nanotubes, have been pre-registered as nanomaterials, REACH
does not specifically mentioned nanomaterials (European Chemical
Agency 2010). One of the limitations of REACH in regard to nanomate-
rials is related to whether a nano-equivalent of a substance with different
physicochemical and (eco)toxicological properties from the bulk sub-
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stance would be considered as the same or as another substance under
REACH (Chaundry et al. 2006). REACH defines a substance as “a chemi-
cal element and its compounds in the natural state or obtained by any manufac-
turing process, including any additive necessary to preserve its stability and any
impurity deriving from the process used, but excluding any solvent which may be
separated without affecting the stability of the substance or changing its composi-
tion.” (EP and CEU 2006, art. 3).
Whether nanomaterials are considered to be a equivalent or different
to the bulk material will have a major impact on the requirements put on
manufacturers prior to placing nanomaterials on the market. If a nano-
material is considered to be a different substance, hazard information
would have to be generated for the registration dossier if produced in
more than 1 tons/year. On the other hand, if the nanomaterial is con-
sidered to be the same as a registered bulk material, the appropriateness
of the hazard information data would be open to discussion (Chaundry
et al. 2006). In 2008, the Commission of European Communities pub-
lished a review of the applicability of REACH arguing that although there
are no specific provisions in REACH referring to nanomaterials the defi-
nition of “a chemical substance” covers nanomaterials (Commission of
European Communities 2008a).
The Commission further stated that: “When an existing chemical sub-
stance, already placed on the market as bulk substance, is introduced on the mar-
ket in a nanomaterial form (nanoform), the registration dossier will have to be
updated to include specific properties of the nanoform of that substance. The addi-
tional information, including different classification and labelling of the
nanoform and additional risk management measures, will need to be included in
the registration dossier. The risk management measures and operational conditions
will have to be communicated to the supply chain” (Commission of European
Communities 2008a, p. 4). It is, however, highly unclear how companies
should do this. Companies are urged to use already existing guidelines.
Both the Commission of the European Communities (2008a) as well as
the its Scientific Committee on Emerging and Newly Identified Health
Risks (SCENIHR 2007, 2009) and others have pointed out that current
test guidelines that support REACH are based on conventional method-
ologies for assessing chemical risks and may not be appropriate for assess-
ing risks associated with nanomaterials. This means that although manu-
facturers and importers might be required to provide a Chemical Safety
Assessment (if they produce or import nanomaterials in volumes more
than 10 tons) they cannot rely on the toxicological profile of the equiva-
lent bulk material and they cannot use existing test and risk assessment
guidelines since these might not provide any meaningful results or be
practically applicable due to the limitations of conventional methods.
It has been reported that the Commission was unable to secure the
endorsement of its view from the Competent Authorities for REACH and
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Classification, Labeling and Packaging (known as CARACAL) (Chemical
Watch 2009) and the European Commission has now launched a multi-
stakeholder project on nanomaterials that intend to look into substance
identification under REACH.
Until recently carbon and graphite were exempted from registration
under REACH, however this exemption was redrawn to address concern
raised about carbonaceous nanomaterials (Führ et al. 2007, C & EN
2008). Companies will now have to register these materials if produced in
quantities above one ton per producer or manufacturer per year. If it is
produced in quantities greater than 10 tons per year a Chemical Safety
Assessment has to be undertaken and if it meets the criteria for classifi-
cation as dangerous or a PBT (Persistent, Bioaccumulative and Toxic) or
vPvB (very Persistent and very Bioaccumulative), the manufacturer is
required to develop exposure scenarios and undertake risk characterisa-
tion(s). So far no nanomaterial has been classified as such. It should be
noted that a Chemical Safety Assessment can also be required if a nano-
material is selected for further evaluation by a Member State or by the
European Chemicals Agency due to specific concerns; or if a substance is
a CMR (Carcinogenic, Mutagenic, or toxic for Reproduction), PBT, vPvB,
ED (Endocrine Disrupting), or substance of equivalent concern. Even
despite the recent amendments to REACH withdrawing carbon and
graphite from the list of exemptions, it is highly unclear whether this
would involve any additional obligations from producers of C60 and car-
bon nanotubes as well as from producers or importers of the final prod-
ucts containing C60 and carbon nanotubes, given what is known and
accessible information about production, product contents, and expect-
ed consumer exposure (Franco et al. 2007). Another issue raised by
Franco et al. (2007) is whether the annual production should be meas-
ured including impurities. All carbon based nanomaterials contain some
degree of impurities due to the manufacturing process, however, a sub-
stance with a different degree of purity and composition can be classified
as the same substance, provided hazardous properties do not differ sig-
nificantly. This means that for instance, raw soot, NanomBlack® and puri-
fied fullerenes from the production of C60 could all be classified as the
same, provided that the hazardous properties do not differ significantly.
Although there is no tonnage related exemption under REACH for
authorization, restriction or classification and labeling requirements, a
second limitation of REACH is that “Substances manufactured or imported in
volumes of less than 1 tons/year do not need to be registered” and hence pro-
ducers or importers are not required to provide toxicological data and
assess environmental exposure. As noted by Chaundry et al. (2006) and
Franco et al. (2007) this threshold would hardly be reached for many
nanoparticles. Chaundry et al. (2006) estimates that the majority of appli-
cations is likely to fall outside the scope of REACH on the basis of the low
European regulation affecting nanomaterials
367
tonnage currently used in gram to kilogram quantities. Furthermore, the
usually low concentration of nanomaterials in the final article could
potentially exclude some nanomaterials from the REACH legislation,
since no registration is required when the concentrations of a substance
in the final article is lower than 0.1% w/w. However, a general lack of
access to information about product formulations and nanoparticles con-
centration hampers determination of concentrations of substances by
weight (Franco et al. 2007).
REGULATION OF COSMETIC PRODUCTS
As the first major piece of legislation to be amended in Europe, the
cosmetics legislation was adapted in 2009 in order to comprise nanoma-
terials (EP and CEU 2009, Bowman et al. 2009).
In the cosmetics regulation a nanomaterial is defined as “an insoluble
or biopersistant and intentionally manufactured material with one or
more external dimensions, or an internal structure, on the scale from 1
to 100 nm”. Acknowledging that there are various definitions of nano-
materials the European Parliament and the Council of the European
Union (CEU) call for the Commission to adjust the definition in the cos-
metics regulation to definitions subsequently agreed at international level
(EP and CEU 2009, art, 2).
For cosmetics already on the market, the regulation requires that the
manufacturers inform the European Commission about the presence of
substances in the form and identity of nanomaterials, and the reasonably
foreseeable exposure conditions (EP and CEU 2009, art. 14). The pres-
ence of nanomaterials in the products has to be clearly indicated in the
list of ingredients by the name of the nanomaterials (e.g. TiO2, silver) fol-
lowed by the word “nano” in brackets e.g. (TiO2 [nano], silver [nano]).
This requirement does however not go into effect until 11 July 2013 (EP
and CEU 2009, art. 19, 40).
For cosmetic products not yet placed on the market the Commission
has to be notified six months prior to commercialization (EP and CEU
2009, art. 16). The notification should include among other: size, physi-
cal and chemical properties of the nanomaterial; quantitative estimates of
amount of nanomaterial to be placed on the market per year; the toxico-
logical profile and the safety data of the nanomaterial relating to the use
of the specific category of cosmetic products and finally, the reasonably
foreseeable exposure conditions. This pre-market notification, however,
only requires if the cosmetic products has not already been placed on the
market before 11 January 2013.
The cosmetic regulation underlines the overarching principle that
any cosmetic product commercialized shall be safe for human health
when used under normal or reasonably foreseeable conditions of use and
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that it is the manufacturers responsibility to ensure that this is the case
(EP and CEU 2009, art, 3, 4).
Prior to placing a cosmetic product on the market Article 10 of the
regulation underlines that the manufacturers have to ensure that a safety
assessment has been performed in accordance with Annex I, which out-
lines the requirements for product safety information and assessment. As
a minimum, it should contain among other a description of the compo-
sition of the cosmetic product and the function of the ingredients, phys-
ical/chemical characteristics and stability of the cosmetic product, micro-
biological quality, normal and reasonably foreseeable use, exposure to
the cosmetic product (site(s) of application, surface area(s) of applica-
tion; amount applied; duration and frequency of use; etc.), toxicological
profile of the substances and notification of undesirable effects and seri-
ous undesirable effects (EP and CEU 2009, annex 1).
In regard to the toxicological profile specifically, the profile has to be
established for all relevant toxicological endpoint considering all signifi-
cant toxicological routes of absorption as well as the systemic effects. A
particular focus has to be on local toxicity evaluation (skin and eye irrita-
tion), skin sensitisation, and photo-induced toxicity in the case of UV
absorption. A margin of safety (MoS) has to be calculated based on a no
observed adverse effects level (NOAEL) (EP and CEU 2009, annex 1).
The proposal from the EP and the Council specifies that particular con-
sideration shall be given to any possible impacts on the toxicological pro-
file due to particle sizes, including nanomaterials. Finally, the product
safety assessment should entail a concluding statement on the safety of
the cosmetic product based on scientific reasoning (EP and CEU 2009,
annex 1).
The cosmetic regulation requires the Commission to request the
Scientific Committee on Consumer Safety (SCCS) to give its opinion
within six months on the safety of such nanomaterial if the Commission
has concerns regarding the safety of a nanomaterial for use in the rele-
vant categories of cosmetic products and on the reasonably foreseeable
exposure conditions. If the SCCS finds that any necessary data is lacking,
it is the responsibility of the manufacturers to provide such data within an
explicitly stated reasonable time period. This time period is non-extend-
able and the SCCS shall deliver its final opinion within six months of sub-
mission of additional data. The request from the Commission as well as
the opinion of the SCCS has to be made publicly available (EP and CEU
2009, art. 16).
Acknowledging that there is inadequate information at present on
the risks associated with nanomaterials the cosmetics regulation requires
the SCCS to provide guidance in cooperation with relevant bodies on test
methodologies which take into account specific characteristics of nano-
materials (EP and CEU 2009, art. 16).
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In regard to restrictions for certain substances, article 16 specifies a
high level of protection of human health shall be ensured for every cos-
metic product that contains nanomaterials (EP and CEU 2009, art. 16).
Taking the SCCS opinion into consideration the Commission may add a
substance to lists of substances prohibited in cosmetic products or which
cosmetic products must not contain except subject to the restrictions laid
down where there is a potential risk to human health, including insuffi-
cient data.
The regulation also specifies that the SCCS should give opinions
where appropriate on the safety of nanomaterials in cosmetic products,
but also underlines that in the case of urgency relating to CMRs, nano-
materials and potential risks to human health of a cosmetic product nor-
mal regulatory procedures do not have to be complied with (EP and CEU
2009, art. 16).
Finally, by 11 January 2014, the Commission has to make a publicly
available catalogue of all nanomaterials used in cosmetic products placed
on the market indicating the categories of cosmetic products and the rea-
sonably foreseeable exposure conditions. Furthermore, the Commission
is obliged to prepare an annual status report for the European
Parliament and the Council outlining e.g. the present and future use of
nanomaterials in cosmetic products, the number of notifications, and the
progress made nano-specific safety assessment methods (EP and CEU
2009, art. 16).
PHARMACEUTICAL REGULATION
Well-described medicinal products containing nanoparticles in the
form of liposomes, polymer protein conjugates, polymeric substances or
suspensions have been given Marketing Authorizations within the EU
under the existing regulatory framework e.g. Regulation 726/2004 on
authorization and supervision of medicinal products for human and vet-
erinary use, Directive 2001/83/EC on medicinal products for human use,
Directive 93/42/EEC concerning medical devices, Directive
90/385/EEC relating to active implantable medical devices, and
Directive 98/79/EC on in vitro diagnostic medical devices (EP and CEU
2004, Council of the European Communities 1990, 1993, 1998, 2001).
There is no specific mentioning of nanomedicine in the EU legisla-
tion on medicinal products and devices, tissue engineering and other
advanced therapies. None of these regulations or directives was written
with nanomedicinal applications in mind and although their scope cov-
ers nanomedicine they have been accused for being general and non-spe-
cific and fraught with concerns and difficulties when it comes to dealing
with drugs more complex than traditional ones (Editorial 2007, D’Silva
and Van Calster 2008). In general it seems to be believed that existing reg-
ulation cover medical products based on nanotechnology and that the
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fairly extensive pre-market safety assessment ensures that the benefits out-
weigh any identified risks or the adverse side-effects, (EGE 2007, N&ET
Working Group 2007).
However, concerns have been raised that risk assessment, safety and
quality requirements for medicine have to be fulfilled by conformity to
established quality systems and published product standards that may not
be suitable designed to address various aspects relating to nanomedicine.
According to the European Medicines Agency (2006a), this might be
especially relevant when it comes to novel applications of nanotechnolo-
gy such as nanostructure scaffolds for tissue replacement, nanostructures
that allow transport across biological barriers, remote control of
nanoprobes, integrated implantable sensory nanoelectronic systems and
multifunctional chemical structures for drug delivery and targeting of
disease. It is furthermore unclear whether novel nanomedicine is to be
regulated as a medicinal product or as a medical device (EGE 2007).
Currently the mechanism of action is key to decide whether a product
should be regulated as one or the other, however, nanomedicinal prod-
ucts may exhibit a complex mechanism of action combining mechanical,
chemical, pharmacological and immunological properties, and combin-
ing diagnostic and therapeutic functions. Hence many of these novel
applications are likely to span regulatory boundaries between medicinal
products and medical devices (EGE 2007, European Medicines Agency
2006a).
When applying a new marketing authorization an environmental risk
assessment is required. Compared to the risk assessment procedure
under REACH, this involves a rough calculation of the predicted envi-
ronmental concentration for surface water. If the PEC is predicted to sur-
pass 0.01 ppb actions have to taken as environmental concerns cannot be
excluded (European Medicines Agency 2006b). The 0.01 ppb threshold
is not science-based and cannot be interpreted as a safe concentration
(European Medicines Agency 2006b). When it comes to nanomedicice a
mass-based action level could furthermore be problematic as mass-based
concentrations might not be the most relevant metrics to describe the
environmental profile of nanomaterials (Zhang et al. 2007, Baun et al.
2008).
Establishing the ecotoxicity of nanoparticles currently holds a num-
ber of limitations and challenges (Stone et al. 2009) and many of these
shortcomings to environmental risk assessment are valid for nanomedical
products as well. For instance, in the EU guidelines for risk assessment of
medical products the octanol-water coefficient is used as surrogate value
for bioaccumulation data, but so far there is no strong evidence that this
approach applies for nanomaterials (SCENIHR 2007, 2009, Handy et al.
2008, Baun et al. 2008).
European regulation affecting nanomaterials
371
NANOFOOD REGULATION
In the EU, food and food packaging are regulated by a number of
directives and regulations such as EU Food Law Regulation and the EU
Novel Foods Regulation (EP and CEU 2002). The EU Food Law
Regulation requires all food to be safe, something which – as an overar-
ching principle – applies to all foods and food packaging containing
nanomaterials as well, but has been criticized for being too loose (FOE
2008). None of the existing EU regulations applicable to agriculture,
food or food packaging currently consider or mention nanoscale prod-
ucts or materials. If a substance as already has been approved for use as
food ingredients, additives or packaging in its bulk form, it can also be
used in this nanoform since there is no regulatory trigger to require new
safety assessment or labeling due to particle size (FOE 2008). The exist-
ing regulation regarding food additives is in the process of being updat-
ed in the EU. During this process the European Parliament’s Committee
on Environment, Public Health and Food Safety stated that it wanted sep-
arate limit values for nanotechnologies and that the permitted limits for
an additive in nanoparticle form should not be the same as when it is in
traditional form (Halliday 2007). The EU Novel Foods Regulation
requires mandatory pre-market approval of all new ingredients and prod-
ucts. Recently, the European Commission adopted a proposal to revise
the Novel Foods Regulation with a view to improving the access of new
and innovative foods to the EU market (Commission of European
Communities 2008b). In the revised regulation the definition of novel
food includes foods modified by new production processes, such as nan-
otechnology and nanoscience, which might have an impact on the food
itself. This proposal recently failed after co-decision procedure where
both the Council of the European Union and the Parliament had to
agree on the final text of the regulation. The main areas of disagreement
between the Council of the European Union and the Parliament in
regard to nanomaterials seem to be the scope of the regulation, the
extend of the novel food definition should include “nanotechnology and
nanoscience” as well as “engineered nanomaterials”, whether or not
labeling should be mandatory and whether or not to have pre-market
safety testing of nanotechnology and nanomaterials in food and packag-
ing (European Parliament 2010).
The lack of adequate information and lack of test methods for assess-
ing the risks of nanomaterials was mentioned by both the Council and the
Parliament in the first line of revisions suggested to the Novel food regu-
lation (European Parliament 2010). At current the European Food Safety
Authority (EFSA) has to evaluate whether or not a novel food and its use
as an ingredient presents a danger to consumers or misleads them once
the European Commission receives an application for authorization of a
novel food. The regulation requires assessments by EFSA on the compo-
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sition, nutritional value, metabolism, intended use and the level of micro-
biological and chemical contaminants. Studies on the toxicology, aller-
genicity and details of the manufacturing process may also be considered.
However, the regulation makes no distinction in relation to particle size,
and hence nanoparticles will not require new safety assessments if the
substance has already been approved in bulk form. In 2009, EFSA pub-
lished a scientific opinion on the potential risks arising from the use of
nanotechnology in food, concluding that nanotechnology aspects shall
be considered when risk assessment guidance documents in the food and
feed area are reviewed. Furthermore, they do, among other, recommend
that risk assessment of nanomaterials in the food and feed area should
consider the specific properties of nanomaterials in addition to those
common to the equivalent non-nanoforms (EFSA 2008). Recently, EFSA
closed for public comments on a draft guidance on risk assessment con-
cerning potential risks arising from applications of nanoscience and nan-
otechnologies to food and feed. This guidance holds practical advice on
how to complete risk assessments of nanomaterials used in food and food
products (EFSA 2011).
SAFETY AT WORKPLACE DIRECTIVES
Safety at workplace in Europe is regulated through the Framework
Directive 89/391 on measures to encourage improvements in the safety
and health of workers as well as Directive 98/24 on the risks associated
with chemical substances (Council of the European Communities 1989,
1998). As in the case of REACH and the Pharmaceutical legislation in
Europe, nanomaterials are not specifically mentioned in these directives.
However, according to the Commission of the European Communities
(2008a) they fully apply to nanomaterials and “...employers, therefore, must
carry out a risk assessment and, where a risk is identified, take measures to elimi-
nate this risk.” The establishment of Occupational Exposure Limits
(OELs) for workers is a key element of the Safety at Workplace directives
however these are typically based on a complete risk assessment proce-
dure which is presently not possible for engineered nanoparticles. OELs
are furthermore typically based on mass concentration, but the most opti-
mal dose metrics is still undefined when it comes to nanoparticles. To
enforce the OELs, methods and equipment to detect nanoparticles in the
workplace are needed. At the moment such methods do not exist which
hampers the effectualness of the OELs (Franco et al. 2007, Stone et al.
2009). Given the lack of OELs specific for nanoparticles, many manufac-
turers refer to OELs of the bulk material. For instance OELs for dusts of
graphite or carbon black instead of C60 and carbon nanotubes. However,
there is evidence in the literature that these OELs are not valid due to the
fundamentally different properties displayed by nanoparticles (Lam et al.
2004, Poland et al. 2008).
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Material Safety Data Sheets (MSDSs) are the key mean to pass infor-
mation about risk and safety down the supply chain. Besides providing
some basic information about the material, the MSDSs also provide work-
ers and emergency personal with information about the risks, protective
equipment and proper handling of a substance as well as the OEL. Given
the problems with establishing appropriate OELs, problems associated
with establishing OELs are reflected in many of the MSDSs made avail-
able by the producers of nanomaterials For instance, there are examples
of MSDSs that list a number of exposure control measures if ‘’engineer-
ing controls do not ensure that the OEL is not exceeded’’, while clearly
stating that OEL cannot be established (Franco et al. 2007).
WASTE MANAGEMENT OF PRODUCTS CONTAINING NANOPARTICLES
In Europe waste is currently primarily regulated through Directive
2008/98/EC of the European Parliament and of the Council on waste
(EP and CEU 2008) and Council Directive 1991/689 on the management
of hazardous waste (Council of the European Communities 1991). None
of these directives mention nanoparticles.
In some cases nano-waste fall under specifically pieces of regulation.
For instance, if C60 is used in oil lubricants, then the used oil is specifi-
cally regulated by Council Directive 75/439/EEC on the disposal of waste
oils. This directive require members states to take measures to ensure safe
collection and disposal of waste oils as well a recycling to the extend pos-
sible (Council of the European Communities 1975). In general, however,
the fate of a given nanoparticles will depend on the treatment of the
nanoproducts when it becomes waste - typically it ends up in landfills or
becomes incinerated. Next to nothing is known about the behavior of
nanoparticles in either of these waste management options. Depending
on degradation of the product in which the nanoparticles are incorpo-
rated as well as their mobility, release might be anticipated through land-
fill leachates. The thermal stability of the specific nanoparticles will deter-
mine their fate during and after products are incinerated. Studies of the
fate and behavior of nanoparticles after incineration are very scarce, but
there are indications that C60 molecules behave like graphite and will be
combusted. Carbon nanotubes remain stable even at very high tempera-
tures (Cataldo 2002). At the moment, lack of (eco)toxicological data
hampers the assessment of whether nanoparticles and some forms of
nano-waste meet the criteria of hazardousness as defined under the
Council Directive 1991/689 on the management of hazardous waste
(Council of the European Communities 1991). Should this be the case
more severe obligations would apply such as limit and emission values for
the content of hazardous substances in waste and requirements for car-
rying out different forms of recovery (Council of the European
Communities 1991, Franco et al. 2007).
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DISCUSSION
Identified limitations of current regulation of nanomaterials
Besides the fact that nanomaterials are not specifically mentioned in
most of the EU legislation analyzed here, it seems as if nanomaterials are
covered by the broad scope of the various pieces of legislation. The
Cosmetic regulation and the Novel food regulation are the exceptions to
this rule and it seems that nanomaterials will be included in one form or
the other. The question is, however, whether nanomaterials are covered
when it comes to the specific procedures and guidelines laid down by the
various pieces of legislation. For REACH the main areas of concern seem
to be that it is unclear when a nano-equivalent of a bulk substance should
be registered under REACH, and that production thresholds for when
(eco)toxicological information has to be submitted, are not currently
met for many nanomaterials (although they might be in the near future).
Furthermore, even though companies are urged to use already existing
guidelines, both the Commission of European Communities (2008a) and
its Scientific Committee on Emerging and Newly-Identified Health Risks
(SCENIHR 2007, 2009) as well as others (Hansen 2009, Stone et al. 2009)
have pointed out that current test guidelines supporting REACH are
based on conventional methodologies for assessing chemical risks and
may not be appropriate for the assessment of risks associated with nano-
materials. Somewhat similar issues have been raised for pharmaceuticals
where the concern is that current product standards may not be suitably
designed to address various aspects relating to novel applications of nan-
otechnology in nanomedicine (Baun and Hansen 2009). Furthermore, if
the estimated environmental concentration of medical products is below
0.01 ppb and “no other environmental concerns are apparent”, no fur-
ther actions are to be taken for the medical product in terms of environ-
mental risk assessment. Such pre-defined action limits could potentially
be problematic as the new properties are expected to affect the environ-
mental profiles of nano-based products (Baun and Hansen 2009).
In our analysis we identified three kinds of potential limitations of the
existing regulatory frameworks when it comes to nanomaterials. In the
first category of limitations are related to the limitations of definitions of
what qualifies as a “substance”, “novel food”, “hazardous waste”, etc. In
the second category falls requirements triggered by thresholds values not
tailored to the nanoscale, but based on bulk material, see e.g. REACH.
The third category of limitations are related to lack of metrological tools,
(eco)toxicological data, occupational and environmental exposure limits
as required by e.g. the pharmaceuticals regulation and the Safety at
Workplace Directives.
These findings are in line with the outcome of other independent
analysis of the current regulation of nanomaterials. In a horizontal scop-
European regulation affecting nanomaterials
375
ing study, Chaundry et al. (2006) assessed the gaps in environmental reg-
ulation in the UK and the EU, media by media and sector by sector focus-
ing on current and future products and applications of nanomaterials. In
total 16 different sectors were included among others coatings, construc-
tion, and cosmetics. Chaundry et al. (2006) found that potential regula-
tory gaps could materialize itself if a) a piece of legislation is intended to
address the human health impacts but fails to address possible environ-
mental impacts of nanomaterials or nanoproducts and b) a piece of leg-
islation fails to address a specific aspect of particular a sector, application,
product or substance due to various threshold-, volume- or tonnage relat-
ed exemptions or limitations in technical or scientific knowledge.
(Chaundry et al. 2006).
Our analysis of the applicability of the current regulation on nano-
materials also showed that (eco)toxicological data and risk assessments
are often necessary to support current regulation. However, risk assess-
ment holds a number of limitations as well, and the short and long term
feasibility of risk assessment of nanomaterials can be discussed. Risk
assessment is often said to consist of four elements i.e. hazard identifica-
tion, dose-response assessment, exposure assessment, and risk characteri-
zation. Each of the four steps hold a number of limitations as well. It is
currently impossible to systematically link reported nanoparticle proper-
ties to the observed effects for effective hazard identification and though
toxicity has been reported on for a range of nanoparticles, further con-
firmation is needed before one can say that a hazard has been identified.
Several of the studies mentioned above have reported on dose-
response relationships. This goes for, especially, in vitro studies on among
other C60, single- and multiwalled carbon nanotubes, and various forms
of nanometals. Normally, dose refers to ‘dose by mass’, however, based on
the experiences gained in biological tests of nanoparticles, it has been
suggested that biological activity of nanoparticles might not be mass-
dependent, but dependent on physical and chemical properties not rou-
tinely considered in toxicity studies (Oberdörster et al. 2005b). For
instance, Oberdörster (1996) and Oberdörster et al. (2007) and Stoeger
et al. (2006, 2007) found that the surface area of the nanoparticles is a
better descriptor of the toxicity of low-soluble, low toxicity particles,
whereas Wittmaack (2007a, b) found that the particle number worked
best as dose metrics. Warheit et al. (2007a, b) found that toxicity was relat-
ed to the number of functional groups in the surface of nanoparticles.
However, it is still an open question which properties determine or influ-
ence the inherent hazards of nanoparticles partly due to the general lack
of characterization of the nanoparticles tested (Hansen et al. 2007).
Hence for dose-response assessment, it is still unclear whether a no-effect
threshold can be established, what the best hazard descriptor(s) of
nanoparticles is, and which are the most relevant endpoints. There is a
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serious lack of characterization of the nanoparticles tested, which makes
it difficult to identify which key characteristics – or combinations of key
characteristics – that determine the hazards documented in (eco)toxico-
logical studies of nanoparticles (Hansen et al. 2007, Wittmaack 2007a).
But perhaps properties not yet identified in the scientific literature may
be relevant for the hazard identification of nanomaterials. Although the
lack of characterization is troublesome, it is hardly surprising as nanotox-
icology is a very young field of research stemming from ultra fine particle
research (Oberdörster et al. 2005a). A true understanding of the haz-
ardous properties that materials begin to exhibit at the nanoscale
requires a level of interdisciplinary research that has not yet been
reached. In order to conduct and interpret scientific studies on the haz-
ardous properties of nanomaterials, strong interdisciplinary collabora-
tion is needed between nanoscientists, (eco)toxicologists and physicists,
chemists, and material engineers.
In regard to exposure assessment (i.e. the third element of risk assess-
ment) several studies have tried to assess current and future consumer
and environmental exposure for nanomaterials, but these should be seen
as “proof of principle” rather than actual assessment of the exposure.
Realistic exposure assessment is hampered by: paucity of knowledge, lack
of access to information, by difficulties in monitoring nanomaterial expo-
sure in the workplace and the environment, and by the fact that the bio-
logical and environmental pathways of nanomaterials are still largely
unexplored. Risk characterization being at the end of the line, the sum
or maybe even the power all of these limitations are conveyed to calcu-
lating risk quotients for nanomaterials.
The European Commission has commissioned an expert-/multi
stakeholder investigation of whether nanospecific amendments are need-
ed to the current technical guidelines on chemical safety assessment. This
has to develop among other specific advice on:
1. How REACH information requirements on intrinsic properties of
nanomaterials can be fulfilled.
2. The appropriateness of the relevant test methods for nanomaterials.
3. Possible specific testing strategies, if relevant.
4. Information needed for safety evaluation and risk management of
nanomaterials (especially, information beyond the current informa-
tion requirements under REACH).
5. How to do exposure assessment for nanomaterials, hazard and risk
characterisation for nanomaterials (Safenano 2010a, b).
The latter will involve threshold/non-threshold considerations, analy-
sis of existing evidence related to setting limit values for nanomaterials,
identification of critical items for dose description (mass, number con-
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centration, surface area, particle size(s) etc.), whether and how no-effect-
levels for health and the environment could be established and finally
development of recommendations on the feasibility of whether categori-
sation of nanomaterials (e.g. different types of carbon nanotubes) in the
hazard assessment compatible with the exposure assessment parame-
ters/metrics in order to prepare a meaningful risk characterization
(Safenano 2010a, b).
Recommendations in regard to the “Incremental approach”
The Commission of the European Communities has adopted a so
called incremental approach which focuses on adapting existing laws to
regulate nanotechnologies and amending them in order to deal with
nanomaterials. In order for the incremental approach to be successful a
number of changes and revision are needed to the regulatory frameworks
analyzed above. So far, the Commission has only found it appropriate to
implement one amendment to the regulatory frameworks analyzed
above, i.e. carbon losing its exemption status under REACH. However,
the other limitations need to be addressed as well sooner rather than later
for the incremental approach to be successful, especially in view of the
current pace of development of nanomaterials and applications. It is rec-
ommended that all nanomaterials are treated as distinct substances
under REACH and other pieces of legislation until it is clarified whether
all or only a few of them display unique (eco)toxicological properties at
the nanoscale. Lowering or changing the current 1 ton per annum
threshold per producer or importer for engineered nanoparticles to dif-
ferent thresholds and units than mass is recommended (RS and RAE,
2004, European Commission, Health and Consumer Protection
Directorate General 2004). This would lead to a separate registration of
nanomaterials under REACH. Besides providing the traditional physico-
chemical properties when registering a substance, producers and
importers of nanomaterials should be obliged to provide additional infor-
mation such as shape, crystal structure, surface- area, charge and chem-
istry paying respect to the specific properties of nanomaterials. The new
European Chemical Agency should develop and provide guidance to pri-
mary manufacturers and down-stream users on safety assessment of nano-
materials and a semi-governmental institution should be established in
order to help industry do nanomaterials’ characterizations and to do
(eco)toxicological testing.
Efforts are underway internationally to identify potential exposure
scenarios at workplaces and establish standard guidelines for safe han-
dling of nanomaterials at the workplace and laboratories as well as iden-
tification of protection measures and development of efficient metrology
infrastructures (NIOSH 2006, 2009, Paik et al. 2008). All of these initia-
tives can and will help address the limitations identified in the Safety at
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Workplace Directives. However, it is expected that the establishment of
Occupational Exposure Levels based on risk assessments is somewhat into
the future and hence it is recommended that occupational exposure of
nanoparticles is limited as much as possible.
Specific environmental regulations (e.g. REACH, Directives on haz-
ardous wastes, etc.) often use terms like ‘’toxic’’ or ‘’persistent’’ as trig-
gering factors to set emission limits, prohibitions and other require-
ments. These regulations require consistent meaning of these terms
which is currently not possible given the lack of (eco)toxicological data
for most nanomaterials. Although work is underway in order to produce
such (eco)toxicological data for nanoparticles, much of this work is only
just getting started and has yet to provide univocal data on which “toxici-
ty” and “persistency” can be established or ruled out (Stone et al. 2009).
Despite the many knowledge and regulatory gaps identified, one of
the largest obstacles is the lack of access to key information along the life
cycle of the products. Key information during production, extraction and
refining, manufacturing, use and final disposal of the products is not
available due to manufacturer’s secrecies and nondisclosure policies. It is
impossible to obtain information on specific production volumes, the
number of product units, concentration of nano-materials/particles in
final products, or mass flows of nanoparticles from the raw material to the
final product. Furthermore quantitative and qualitative characterizations
of by-products, such as fullerenic soot and carbon nanotube fibres, as well
as their fate cannot be exhaustively described. Without such information,
public authorities will have a hard time monitoring and evaluating the
effectiveness of the incremental approach. Some claims of confidential
business information seem unreasonable (Hansen and Rejeski, 2008),
and providing wider access to at least some information seems to be an
important step in facilitating the availability of information up-and-down
the supply chain and to other interested parties. In the case of emerging
technologies, including nanomaterials, at a minimum information made
publicly available for regular substances under REACH should also be
made available i.e.: name, classification and labeling, physicochemical
data, including information on pathways and environmental fate, results
of each toxicological and ecotoxicological study, any derived no-effect
level or predicted no effect concentration, guidance on safe use, and, to
the extend possible, analytical methods for detecting direct human expo-
sures or discharge to the environment.
Implementation of these recommendations will only address some of
the immediate concerns related to the application of the incremental
approach to regulate current manufacturing and use of nanomaterials.
However, they fail to address other concerns, especially the ones related
to nanomaterial yet to be developed, i.e. the third and fourth generation
of nanotechnological development. More work is needed to cave out
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what the impact of future generations of nanotechnology will be on
European legislation.
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